Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 10 of 3092 for:    Area Under Curve AND Healthy

PK Study to Evaluate the Effect of PLC on Healthy Chinese Subjects by Multiple-doses

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02786043
Recruitment Status : Completed
First Posted : May 30, 2016
Last Update Posted : May 30, 2016
Sponsor:
Information provided by (Responsible Party):
Lee's Pharmaceutical Limited

Brief Summary:
The main objective is to evaluate the effect of Propionyl-L-Carnitine Hydrochloride on clinical pharmacokinetic characteristics and its effect of clinical pharmacokinetic characteristics and safety on healthy Chinese subjects to provide a basis for market authorization registration

Condition or disease Intervention/treatment Phase
Peripheral Arterial Diseases Drug: Propionyl-L-Carnitine Hydrochloride Phase 1

Detailed Description:
This is a single group subject, open-label, self-controlled, 3 periods, multi-doses administration trial. 12 Healthy Chinese volunteers satisfying inclusion criteria were enrolled with equal number of male and female. Each subject goes through a 7-day Run-in period to eliminate the remaining L-carnitine like substance in the food to ensure the baseline level of endougenous L-Carnitien is stable;In period III, during the first 4 days,all healthy subjects take oral Propionyl-L-Carnitine 1g twice daily; on day 5, all healthy subjects take oral Propionyl-L-Carnitine 1g during fasting.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Single Arm, Self-controlled Safety and Pharmacokinetics Study to Evaluate the Effect of Propionyl L-carnitine Hydrochloride on Healthy Chinese Subjects by Diet and Multiple-doses
Study Start Date : June 2015
Actual Primary Completion Date : November 2015
Actual Study Completion Date : January 2016

Resource links provided by the National Library of Medicine

Drug Information available for: Carnitine

Arm Intervention/treatment
Experimental: Single arm Drug: Propionyl-L-Carnitine Hydrochloride
1g twice a day on first 4 days and 1g/ day on day 5 during Phase III




Primary Outcome Measures :
  1. Area Under Curve (AUC) [ Time Frame: Day 3 and 4, 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24h after drug administration on day 5 ]
    To observe area under curve characteristics of Propionyl-L-Carnitine in single or multiple dose groups


Secondary Outcome Measures :
  1. cumulative urine excretion rate [ Time Frame: 0h-2h, 2-4h, 4-8h, 8-12h, 12-24h after drug administration ]
    To compare the cumulative urine excretion rate in multiple dose with that in single dose



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Sex: Male and female of same proportion. Healthy individuals.
  • Age: 19 to 45. Similar age.
  • Weight: All subjects need to weigh ≥50 kg. BMI within 19~24 kg/m2. Similar weight between subjects.;
  • Blood pressure: SBP 90-139mmHg,DBP 60-89 mmHg;
  • Subjects need to understand and agree before the start of trial and signed the informed consent form.
  • Subjects have to be able to communicate with the investigator and comply with the trial protocol.

Exclusion Criteria:

Laboratory investigations:

  • Any items of safety evaluation index baseline values considered to be clinically significant abnormal by the investigator before the study;
  • Hepatitis B surface antigen positive;
  • Hepatitis C antibody positive;
  • HIV, Syphilis positive;
  • During screening or 1st day of trial before drug administration, any ECG abnormality shown

Drug history:

  • Taken any drugs that inhibit or induce hepatic metabolism of drug 1 month prior to the trial;
  • Taken any drugs within 2 weeks prior to the trial (including prescription drugs, non-prescription drugs and Chinese herbal drugs);

Past medical history and surgical history:

  • Past medical history includes structural heart diseases, heart failure, myocardial infarction, angina pectoris, unexplained arrhythmias, Torsade de pointes, ventricular tachycardia, Long QT syndrome or signs and symptoms of Long QT syndrome with family history (evidenced by genetic testing or relatives died of sudden cardiac death at a young age);
  • Thyroid disease history or received thyroid surgery;
  • Immune diseases history (e.g. thymus disorder history);
  • Received surgery within 6 months prior to the trial;
  • Serious gastrointestinal disease history (e.g. clinically significant gallbladder disease, known or suspected jaundice, hepatocellular adenoma, hepatic cavernous hemangioma or other hepatic disease);
  • Any gastrointestinal, hepatic or renal diseases that affect drug absorption or metabolism within 6 months prior to the trial (excluded regardless resolved);
  • Any serious cerebrovascular, respiratory, metabolic and neurological disease history;
  • Hematological disease like clotting disorder;
  • Tumor history;
  • Hypokalemia, hypocalcemia according to the lower limit of reference range provided by the clinical laboratory;

Lifestyle:

  • Frequent alcohol intake within 6 months prior to the trial. Over 14 units of alcohol intake per week (1 unit = 17.7ml ethanol, 1 unit = 357 ml 5% alcohol beer or 44ml 40% liquor or 147 ml 12% alcohol wine);
  • Smoke >1 cigarette per day within 3 months prior to the trial;
  • Drug abuse history and taken drugs (marijuana, cocaine, opiates, benzodiazepines, amphetamines, barbiturates, methadone, tricyclic antidepressants, etc.) within 1 year prior to the trial;
  • Drink excess tea, coffee or caffeine-containing drinks (more than 8 cups) per day 2 days before drug administration to 8 days after drug administration;
  • Drink grapefruit juice 2 days before drug administration to 8 days after drug administration;

Others:

  • Did not consent to use effective contraceptive methods from enrollment to 3 months after drug administration;
  • Hypersensitivity including known allergy to the excipients of the drug (microcrystalline cellulose, lactose, silica powder, sodium carboxymethyl starch, magnesium stearate);
  • Participated in any other clinical trials within 3 months prior to the trial or planned to participate in any other clinical trials 1 month after enrollment to the last drug administration visit;
  • Blood donation within 3 months prior to the trial or planned to donate blood 1 month after enrollment to the last drug administration visit;
  • Any food allergy or special request to diet and cannot comply to unified diet;
  • Subjects considered to be excluded by investigator;

For female subjects, any following criteria met, apart from criteria above, should also be excluded:

  • Taken oral contraceptive pills within 1 month prior to the trial;
  • Long term use of estrogen or progesterone injection or implants within 6 months prior to the trial;
  • Fertile female subjects without using contraceptive method 2 weeks prior to the trial;
  • Fertile female subjects and spouse not consent to use following contraceptive method, condoms, intra-uterine device, etc. after enrollment to 3 months after drug administration;
  • During pregnancy or lactation;
  • Urine pregnancy test positive;

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02786043


Sponsors and Collaborators
Lee's Pharmaceutical Limited
Investigators
Layout table for investigator information
Principal Investigator: Heng-yan Qu National Clinical Trial Institution of Affiliated Hospital of Military Medical Sciences

Layout table for additonal information
Responsible Party: Lee's Pharmaceutical Limited
ClinicalTrials.gov Identifier: NCT02786043     History of Changes
Other Study ID Numbers: Zhaoke-201506-PLC-multidose
First Posted: May 30, 2016    Key Record Dates
Last Update Posted: May 30, 2016
Last Verified: April 2016

Additional relevant MeSH terms:
Layout table for MeSH terms
Peripheral Arterial Disease
Peripheral Vascular Diseases
Atherosclerosis
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases